BMO Capital Downgrades Eli Lilly & Co to Sell

By Ryan Adsit

Eli Lilly & Co (NYSE: LLY) received a Sell rating and a $71 price target from BMO Capital analyst Alex Arfaei on April 17. The company’s shares closed yesterday at $80.89.

According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 3.9% and a 57.9% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Kindred Biosciences, Merck & Company, and Valeant Pharma.

Eli Lilly & Co has an analyst consensus of Moderate Buy, with a price target consensus of $85.50.

Based on the recent corporate insider activity of 102 insiders, corporate insider sentiment is negative on the stock. Last month, Lilly Endowment Inc, a Major Shareholder at LLY sold 210,000 shares for a total of $17,780,700.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. It operates through the Human Pharmaceutical Products and Animal Health segments. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular, and other. The Animal health segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The Other Pharmaceuticals products include anti-infectives, primarily Vancocin and Ceclor, and other miscellaneous pharmaceutical products and services. Its products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.